88 completed, 11 unknown, 10 terminated, 9 withdrawn. 41 Phase 3, 36 Phase 2, 27 Phase 4, 7 Phase 1, 4 Not applicable.
Follow OnabotulinumtoxinA: new trials by email Literature Review of OnabotulinumtoxinA trials Research Report on OnabotulinumtoxinA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines | Phase 2 | Recruiting | AbbVie | 300 | 2026-10-07 | 2026-10-13 |
| Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine Ultrasound-guided pulsed radiofrequency (PRF), OnabotulinumtoxinA - Chronic Migraine Headache | Phase 4 | Not yet recruiting | Assiut University | 70 | 2026-10-01 | 2026-09-22 |
| Comparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine OnabotulinumtoxinA, Ultrasound-guided pulsed radiofrequency (PRF) of the greater occipital nerve (GON) and supratrochlear nerve - Chronic Migraine | Phase 4 | Not yet recruiting | Assiut University | 70 | 2026-10-01 | 2026-09-23 |
| Study to Assess Participant Satisfaction After Jawline and Neck Treatment OnabotulinumtoxinA, SKINVIVE, VOLUX - Jawline and Neck Appearance | Phase 4 | Recruiting | AbbVie | 100 | 2026-09-09 | 2026-10-08 |
| Botulinum Toxin and/or Greater Occipital Nerve Block for Patients With Chronic Migraine OnabotulinumtoxinA, Greater Occipital Nerve Block (GONB) - Chronic Migraine Headache, OnabotulinumtoxinA | Not applicable | Not yet recruiting | Beni-Suef University | 90 | 2026-04-01 | 2026-04-17 |
| Cleft Lip Scarring After Botox Botulinum Toxin Type A (BOTOX) Injection, Normal Saline - Cleft Lip, Cleft Lip Scar | Phase 2 | Recruiting | Children's National Research Institute | 40 | 2026-02-19 | 2026-10-19 |
| Efficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis. OnabotulinumtoxinA, Normal saline (placebo) - Base-of-thumb Osteoarthritis, Osteoarthritis | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2025-12-03 | 2026-04-03 |
| Preoperative BOTOX® Injection for Large Ventral Hernia Repair OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA - Hernia Abdominal Wall, Botox Injection | Phase 4 | Recruiting | The Cleveland Clinic | 188 | 2025-11-03 | 2026-10-26 |
| A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) AGN-151586, OnabotulinumtoxinA, Placebo - Glabellar Lines | Phase 1 | Completed | AbbVie | 132 | 2025-02-18 | 2025-11-17 |
| A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants OnabotulinumtoxinA, Placebo - Forehead Lines | Phase 3 | Completed | AbbVie | 150 | 2025-01-22 | 2026-05-05 |
| A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products OnabotulinumtoxinA, JUVÉDERM, CoolSculpting Elite System - Facial Contouring | Phase 4 | Completed | AbbVie | 130 | 2025-01-16 | 2026-05-22 |
| Efficacy of Focused Shock Wave Therapy Before and After Botulinum Toxin Injection in Patients With Post-Stroke Spastic Equinus/Equinovarus Foot: A Randomized Clinical Trial Botulinum toxin type A, Focal Extracorporeal Shock Wave Therapy (ESWT) - Post-Stroke Spasticity, Spastic Equinovarus Foot | Not applicable | Active not recruiting | María Belén Martínez Luna | 69 | 2024-10-10 | 2026-08-11 |
| Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery OnabotulinumtoxinA, Placebo - Head Neck Cancer, Xerostomia Following Radiotherapy | Phase 2 | Not yet recruiting | Sir Mortimer B. Davis - Jewish General Hospital | 50 | 2024-10-01 | 2024-07-31 |
| Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation Botulinum toxin type A - Wrinkle | Withdrawn | Global Aesthetics LLC | 2024-05-22 | 2026-08-12 | ||
| A Study to Evaluate Adverse Events and Effectiveness of OnabotulinumtoxinA in Participants Undergoing Open Abdominal Ventral Hernia Repair for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique BOTOX Dose A, Placebo for BOTOX, BOTOX Dose B - Ventral Hernia, Abdominal Hernia | Phase 2 | Withdrawn | AbbVie | 2024-05-07 | 2024-05-16 | |
| A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants BOTOX, Placebo - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 207 | 2024-04-30 | 2026-08-12 |
| A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence BOTOX, Placebo - Masseter Muscle Prominence | Phase 3 | Completed | AbbVie | 202 | 2024-04-22 | 2026-08-25 |
| A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines BOTOX - Upper Facial Lines | Phase 4 | Completed | AbbVie | 100 | 2024-02-05 | 2025-11-24 |
| Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity ABBV-950, BOTOX, Placebo for ABBV-950 - Upper Limb Spasticity | Phase 1 | Terminated | AbbVie | 1 | 2024-01-12 | 2024-07-01 |
| A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA, Placebo - Moderate to Severe Glabellar Lines | Phase 3 | Completed | Chongqing Claruvis Pharmaceutical Co., Ltd. | 529 | 2023-12-28 | 2024-07-24 |
Showing 20 of 129. Sign in to see all of them.
Urinary Bladder, Overactive (16) · Muscle Spasticity (12) · Urinary Incontinence (12) · Migraine Disorders (10) · Stroke (9) · Cerebral Palsy (4) · Headache (3) · Prostatic Hyperplasia (3) · Torticollis (3) · Bruxism (2) · Hernia, Abdominal (2) · Hernia, Ventral (2) · Osteoarthritis (2) · Pelvic Pain (2) · Urinary Bladder, Neurogenic (2)
Allergan (49) · AbbVie (17) · Cady, Roger, M.D. (3) · Assiut University (2) · Chongqing Claruvis Pharmaceutical Co., Ltd. (2) · National Cheng-Kung University Hospital (2) · University of California, Irvine (2) · AboutSkin Dermatology and DermSurgery, PC (1) · Assistance Publique - Hôpitaux de Paris (1) · Augusta University (1) · Benha University (1) · Beni-Suef University (1) · Cairo University (1) · Children's National Research Institute (1) · Christopher Patrick Smith (1)
United States (78) · Canada (28) · France (11) · Germany (10) · Belgium (9) · South Korea (9) · United Kingdom (9) · Poland (8) · Czechia (7) · China (6) · Italy (5) · Russia (5) · Spain (5) · Taiwan (5) · Turkey (Türkiye) (5)
Arlene Lum (2) · Dana Fetterolf (2) · Roger K Cady, MD (2) · Yan Wu (2) · Ahana Gaurav (1) · Ahunna Ukah (1) · Alan A Harvey, DMD (1) · Aleks Zuzek (1) · Alexander Pantelyat, MD (1) · Amin Boroujerdi (1) · Amy Krambeck, MD (1)
PMID 24754838, PMID 26231052, PMID 32665528, PMID 33955921, PMID 11743295, PMID 15291863, PMID 15985582, PMID 17105455, PMID 17504651, PMID 17682008, PMID 18478352, PMID 19054163, PMID 20396496, PMID 23098762, PMID 23608668, PMID 26133547, PMID 26509943, PMID 27666156, PMID 28367260, PMID 28840969, PMID 29404713, PMID 29753118, PMID 29877131, PMID 30612462, PMID 30630956, PMID 31559634, PMID 31609787, PMID 31953896, PMID 32719964, PMID 32985341, PMID 33040610, PMID 33106278, PMID 33151636, PMID 33955918, PMID 34245684, PMID 34404257, PMID 36325678, PMID 36849797, PMID 37160401, PMID 37260130, PMID 38206635, PMID 38813838, PMID 39801092, PMID 41025675, PMID 41393002
2014 (4)